The recommended subscription price is 20.4-21.9 yuan. According to our profit forecast, the company achieved diluted earnings per share of 0.73 yuan, 0.91 yuan, and 1.07 yuan in 2012, 2013, and 2014. Using the predicted price-earnings ratio for 2012 between 28 and 30 times, the recommended subscription price range is 20.4-21.9 yuan.
【东方证券】双成药业:化学合成多肽领域领先企业
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.